Suraj Kalia
Stock Analyst at Oppenheimer
(3.87)
# 644
Out of 5,152 analysts
91
Total ratings
48.72%
Success rate
11.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Downgrades: Perform | n/a | $25.35 | - | 3 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $150 → $175 | $140.07 | +24.94% | 12 | Feb 25, 2026 | |
| PODD Insulet | Maintains: Outperform | $365 → $300 | $240.94 | +24.51% | 1 | Feb 19, 2026 | |
| ATRC AtriCure | Downgrades: Perform | n/a | $30.31 | - | 8 | Feb 18, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $140 → $132 | $111.04 | +18.88% | 2 | Jan 23, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $125 → $100 | $72.99 | +37.01% | 1 | Jan 16, 2026 | |
| INSP Inspire Medical Systems | Upgrades: Outperform | $175 | $62.46 | +180.18% | 3 | Dec 8, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $23 → $18 | $12.58 | +43.08% | 7 | Nov 19, 2025 | |
| EW Edwards Lifesciences | Downgrades: Perform | n/a | $83.89 | - | 6 | Oct 8, 2025 | |
| PLSE Pulse Biosciences | Initiates: Outperform | $22 | $18.58 | +18.41% | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $120 | $126.95 | -5.47% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $37.86 | -15.48% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $90 → $93 | $106.15 | -12.39% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.77 | +109.64% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $3.72 | +249.46% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $85.23 | +58.39% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $255.32 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $29.46 | +1.83% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $320 → $200 | $0.83 | +24,037.10% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $77.11 | +25.79% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $20.12 | +39.17% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $3.76 | +19.68% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.09 | +1,367.89% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $496.70 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $2.59 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $18.60 | +437.63% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $70.69 | - | 5 | Sep 12, 2018 |
PROCEPT BioRobotics
Feb 26, 2026
Downgrades: Perform
Price Target: n/a
Current: $25.35
Upside: -
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $150 → $175
Current: $140.07
Upside: +24.94%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $365 → $300
Current: $240.94
Upside: +24.51%
AtriCure
Feb 18, 2026
Downgrades: Perform
Price Target: n/a
Current: $30.31
Upside: -
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $140 → $132
Current: $111.04
Upside: +18.88%
Boston Scientific
Jan 16, 2026
Maintains: Outperform
Price Target: $125 → $100
Current: $72.99
Upside: +37.01%
Inspire Medical Systems
Dec 8, 2025
Upgrades: Outperform
Price Target: $175
Current: $62.46
Upside: +180.18%
Varex Imaging
Nov 19, 2025
Maintains: Outperform
Price Target: $23 → $18
Current: $12.58
Upside: +43.08%
Edwards Lifesciences
Oct 8, 2025
Downgrades: Perform
Price Target: n/a
Current: $83.89
Upside: -
Pulse Biosciences
Jul 7, 2025
Initiates: Outperform
Price Target: $22
Current: $18.58
Upside: +18.41%
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $126.95
Upside: -5.47%
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $37.86
Upside: -15.48%
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $106.15
Upside: -12.39%
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $4.77
Upside: +109.64%
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $3.72
Upside: +249.46%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $85.23
Upside: +58.39%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $255.32
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $29.46
Upside: +1.83%
Jun 23, 2023
Maintains: Outperform
Price Target: $320 → $200
Current: $0.83
Upside: +24,037.10%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $77.11
Upside: +25.79%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $20.12
Upside: +39.17%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $3.76
Upside: +19.68%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $1.09
Upside: +1,367.89%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $496.70
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $2.59
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $18.60
Upside: +437.63%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $70.69
Upside: -